Background. Controversy exists whether mood disorders, such as depression, are associated with Lyme borreliosis (LB). The study objective was to assess prevalence of depressive symptoms in subgroups of patients referred to a tertiary Lyme center, to investigate whether depressive symptoms can be used in clinical practice to discriminate for LB.
Lyme borreliosis (LB) is caused by the bacterium Borrelia burgdorferi, which is transmitted to humans by ticks. There are several objective clinical presentations of LB, with a localized infection manifested as an erythema migrans (EM) or borrelial lymphocytoma [1] . Clinical manifestations of disseminated disease include multiple EM, Lyme neuroborreliosis, Lyme carditis, Lyme arthritis, and acrodermatitis chronica atrophicans (ACA) [1] . The Dutch National Guidelines for Lyme Disease recommend serological testing for Borrelia burgdorferi using a 2-tier testing strategy, in which positive or equivocal enzymelinked immunosorbent assay (ELISA) results are confirmed by immunoblots [1, 2] . In the Netherlands, first-choice treatment for a localized EM is doxycycline for 10 days [2] . This leads to cure at 12 months in 83.7% of cases [3] . Therefore, for the large majority of patients, when timely and adequately diagnosed and treated, LB is not an insidious illness [4] .
In the Netherlands, the incidence of general practitioner consultations for tick bites and the incidence of EM diagnoses increased between 1994 and 2009; by 2014, the incidence of general practitioner consultations for tick bites decreased to 488 per 100 000 inhabitants and the incidence of EM diagnoses stabilized at 140 per 100 000 inhabitants [5] . In the Netherlands, diagnosis and treatment of localized EM is mostly done by general practitioners. In case of other manifestations of LB or atypical symptoms of LB, patients can be referred by general practitioners to medical specialists either to secondary care or directly to tertiary care. The tertiary Lyme Center Apeldoorn is part of Gelre Hospital and consists of a multidisciplinary center including neurologists, internists, infectious disease specialists, epidemiologists, and medical microbiologists, who rely on dedicated cardiologists, rheumatologists, and dermatologists. Patients suspected of LB are referred from all over the Netherlands and at first visit they are seen by an internist and neurologist at the same time to optimize care. The Lyme Center Apeldoorn serves as a secondary and tertiary care center and is located in a highly endemic region for LB in the center of the Netherlands [5] .
There is controversy in the literature as to whether atypical persistent symptoms may occur after possibly unnoticed manifestations of early LB, regardless of whether a patient received appropriate antibiotic treatment [4, [6] [7] [8] [9] [10] . These atypical symptoms can consist of fatigue, musculoskeletal pain, and neurocognitive difficulties [10] , but might also include mood disorders, such as depression [11] . Published results on an association between depression and LB are contradictory [12] [13] [14] [15] [16] [17] . Moreover, comparison of these studies is hampered due to different study designs, case definitions, control groups, depression inventories, and small sample sizes. Our study objective was to assess the prevalence of depressive symptoms among subgroups of patients with and without LB referred to a tertiary Lyme center, to investigate whether depressive symptoms can be used in clinical practice to discriminate for LB.
METHODS
All adult patients who visited the tertiary Lyme Center Apeldoorn between January 2008 and December 2014 were included in this cohort study. Patients were excluded if they did not have medical consultation and/or diagnostic testing with both an immunoglobulin G (IgG) ELISA and IgG immunoblot result. Prior to medical consultation, serum samples were taken and patients completed a digital questionnaire on the occurrence and severity of 49 symptoms. In addition, the questionnaire comprised the Dutch version of the Beck Depression Inventory II (BDI-II) [18, 19] . This self-administered questionnaire consisted of 21 items to assess severity of symptoms indicative for depression. For each item, patients were asked to choose 1 of 4 statements that applied to their mood. Total score ranged from 0 to 63. BDI-II scores of 0-13 were categorized as minimal depressive symptoms, 14-19 as mild depressive symptoms, 20-28 as moderate depressive symptoms, and 29-63 as severe depressive symptoms [19] . It should be noted that the BDI-II is not a diagnostic tool for depression, but a screening tool for patients who might benefit from psychological referral for further diagnostics for depression. The following data were retrospectively, systematically extracted from the patient's electronic medical record using standard data-entry forms: clinically observed LB with localized EM or lymphocytoma, or manifestations of disseminated LB (ie, Lyme neuroborreliosis, Lyme arthritis, Lyme carditis, ACA, or multiple EM), history of localized or disseminated LB, history of tick bites, (previous) antibiotic treatment(s), and demographic characteristics.
Serological testing was performed at the department of Medical Microbiology of Gelre Hospital. Serological testing was performed using an IgG ELISA (Enzygnost Lyme link VlsE/IgG, Dade Behring) followed by an IgG immunoblot (recomLine Borrelia IgG, Mikrogen) irrespective of objective clinical findings or the outcome of the ELISA. This is usual practice at Gelre Hospital. The commercially available Enzygnost Lyme link VlsE/IgG (Dade Behring) was a quantitative method based on a combination of native Borrelia antigens and recombinant VIsE [20] . The concentration of Borrelia antibodies in serum was quantified and expressed as international units (IU)/mL. Cutoff values were as follows: <6 IU/mL as negative, 6-49 IU/mL as equivocal, 50-199 IU/mL as weak positive, 200-499 IU/mL as positive, 500-999 IU/mL as strong positive, and ≥1000 IU/mL as extreme strong positive. The commercially available immunoblot recomLine Borrelia IgG (Mikrogen) was used to detect IgG antibodies in serum. A sum of scores was calculated based on the presence of IgG antibodies in serum: p100 had score 5, VlsE score 5, p58 score 4, p41 score 1, p39 score 5, OspA score 5, OspC score 5, and p18 score 5. Depending on the combinations of different antibodies that bind with antigens, the outcome was negative (sum of scores ≤5), equivocal (sum of scores = 6), or positive (sum of scores ≥7) as defined in the manufacturer's instructions for use [21, 22] .
Patients were classified into 1 of the following 4 categories based on objective clinical findings in combination with serology results: (1) no clinical LB and negative serology; (2) no clinical LB and positive serology; (3) clinical LB and negative serology; and (4) clinical LB and positive serology. Clinical LB was defined according to European case definitions for LB [23] as having an EM (ie, expanding red or bluish-red patch [≥5 cm in diameter], with or without central clearing; advancing edge typically distinct, often intensely colored, not markedly elevated) or lymphocytoma (ie, painless bluish-red nodule or plaque on ear lobe, ear helix, nipple, or scrotum), or clinical findings of disseminated LB including Lyme neuroborreliosis (ie, meningoradiculitis, meningitis, facial palsy, encephalitis, myelitis, or cerebral vasculitis), Lyme arthritis (ie, recurrent attacks or persisting objective joint swelling in 1 or few large joints; alternative explanations excluded), Lyme carditis (ie, atrioventricular [I-III] conduction disturbances, rhythm disturbances, myocarditis or pancarditis; alternative explanations excluded), ACA (ie, long-standing red or bluish-red skin lesions, usually on the extensor surfaces of extremities; initial doughy swelling; lesions eventually become atrophic; possible skin induration and fibroid nodules over bony prominences), or multiple EM either at the time of medical consultation or in the past. Positive serology was defined as having a positive or equivocal IgG ELISA in combination with a positive or equivocal IgG immunoblot. Negative serology was defined as a negative IgG immunoblot irrespective of the IgG ELISA outcome. Patients with a negative IgG ELISA and positive IgG immunoblot were described, but not classified and excluded from further analyses.
Descriptive analyses were performed to assess frequencies of clinical LB in combination with serology results, as well as frequencies of localized and disseminated Lyme manifestations. Disseminated LB was further classified as active (ie, antibiotic treatment for LB following medical consultation or, if suspected for Lyme carditis, additional electrocardiogram [ECG]) or past (ie, no antibiotic treatment for LB following medical consultation or additional ECG) LB. In addition, descriptive analyses were performed to assess the prevalence of depressive symptoms (ie, minimal, mild, moderate, severe) among the above-mentioned patient groups (ie, clinical LB and positive serology, clinical LB and negative serology, no clinical LB and positive serology, no clinical LB and negative serology). Using univariate logistic regression analyses, odds ratios (ORs) with 95% confidence interval (CI) were calculated for moderate/ severe depressive symptoms (BDI-II scores ≥20) in each of the patient groups. Using multivariate analyses, ORs corrected for age and sex were obtained. Additional subgroup analyses were performed to compare the prevalence of moderate/ severe depressive symptoms in patients with localized EM vs disseminated LB irrespective of serology results. Statistical analyses were performed in SPSS version 23.0 (SPSS Inc, Chicago, Illinois).
Because data were collected as part of usual care, this study falls outside the scope of the Dutch Medical Research Involving Human Subjects Act, and no informed consent was required. This was supported by the Medical Ethics Committee of Isala Hospital, Zwolle, the Netherlands.
RESULTS
In total, 1573 patients were referred to the Lyme Center Apeldoorn suspected of LB. Eighty patients were excluded as they were aged <18 years. Twenty-eight patients did not have both an IgG ELISA and IgG immunoblot tested. Of these 28 patients, for 16 patients the results of the IgG ELISA were missing and for 12 patients the results of the IgG immunoblot were missing. Eleven patients had diagnostic testing, but never visited the specialist for medical consultation, and clinical data were missing. Included were 1454 patients with a median age of 51 years (range, 18-87) from which 51.2% were female.
Of 1454 patients, 30.1% (437) had no clinical LB and negative serology, 17.5% (255) had no clinical LB and positive serology, 30.0% (436) had clinical LB with negative serology, and 20.6% (300) had clinical LB with positive serology. In addition, 1.8% (26) of patients could not be classified as these patients had a negative IgG ELISA in combination with an equivocal or positive IgG immunoblot, although 17 of these 26 patients had a history of an EM, and 1 patient had neuroborreliosis in the past.
Of patients with clinical LB and positive serology, 58.3% (175/300) concerned localized LB and 41.7% (125/300) concerned disseminated manifestations of LB. Of patients with clinical LB and negative serology, this was 90.1% (393/436) and 9.9% (43/436), respectively. Of 43 patients with clinical disseminated LB and negative serology, 41 concerned past infections and 2 concerned active infections, of which 1 was suspected for multiple EM and 1 for neuroborreliosis. The median time between starting date of the EM and medical consultation was 22 months (range, 0-327 months) for patients with positive serology vs 26.5 months (range, 0-523 months) for patients with negative serology. The distribution of active and past disseminated manifestations of LB is shown in Table 1 .
The overall median BDI-II score was 13. The median BDI-II score was 15 for patients with no clinical LB and negative serology; 11 for patients with no clinical LB and positive serology; 12 for patients with clinical LB and negative serology; and 12 for patients with clinical LB and positive serology. Table 2 shows the prevalence of depressive symptoms in the 4 patient groups. The prevalence of depressive symptoms was lowest in patients with no clinical LB and positive serology (15.3%), and highest in patients with no clinical LB and negative serology (29.3%) ( Table 3 ). The adjusted OR for depressive symptoms in patients with clinical LB and positive serology was 0.71 (95% CI, .50-1.03) compared to patients with no clinical LB and negative serology.
Subgroup analyses demonstrated that the prevalence of depressive symptoms in patients with localized LB was 20.2% (115/568), and also 20.2% (34/168) in patients with disseminated LB (OR, 1.00; 95% CI, .65-1.54).
DISCUSSION
This study shows that in patients referred to a tertiary Lyme center, depressive symptoms are common. The prevalence of depressive symptoms was similar in patients with LB compared to patients with no evidence of infection. This suggests that depressive symptoms cannot be used to discriminate for LB in a tertiary Lyme center.
The prevalence of depressive symptoms in patients with no clinical LB and positive serology and in patients with clinical LB and negative serology was significantly lower compared to patients with no clinical LB and negative serology. Patients with no clinical LB and positive serology may be asymptomatic patients who possibly acquired immunity in a Lyme-endemic region, or some of these patients could be false-positives. Patients with clinical LB and negative serology represent patients with a history of LB, and some might be false-negatives. One patient suspected of neuroborreliosis (with IgG-positive cerebrospinal fluid (CSF)) and 1 patient suspected of multiple EM had negative IgG serology. It may be that these patients were infected by other Borrelia genospecies that could not be identified with the diagnostic test. In addition, 26 patients had a negative IgG ELISA and positive or equivocal IgG immunoblot. According to the guidelines, these patients were considered to have negative serology, as an immunoblot after a negative ELISA is not recommended [2] . However, 17 of these 26 patients had a history of EM and 1 patient experienced neuroborreliosis in the past.
Although the prevalence of depression in Lyme patients has been investigated before, comparison of study results is hampered due to different study designs, case definitions, control groups, depression inventories, and small sample sizes. In a randomized controlled trial where seropositive and seronegative patients with a history of Lyme disease were compared, the mean BDI score at baseline was similar (11.2 vs 12.9, respectively) [16] . In our study we also found a similar prevalence of depressive symptoms in patients with clinical LB and positive and negative serology. In a study where the mean BDI score of patients with Lyme neuroborreliosis was compared to the mean BDI score of healthy controls, no significant difference was found (5.3 vs 3.2, respectively) [15] .
We compared our results with the prevalence of depressive symptoms in chronic diseases. In a study on depressive symptoms in patients with rheumatoid arthritis, 22.5% had moderate depressive symptoms and 18.6% had severe depressive symptoms assessed with the BDI-II [24] . The prevalence of depressive symptoms was found to be 24.6% in a systematic meta-analysis including 39 587 individuals with chronic obstructive pulmonary disease (COPD) [25] . However, in this meta-analysis, depressive symptoms were assessed with other inventories than the BDI-II. Our prevalence of 19.3% in patients with clinical LB and positive serology was lower than the prevalence in COPD and rheumatoid arthritis patients.
The Dutch version of the BDI-II was used to assess depressive symptoms [18, 19] . Although the reliability and validity of the BDI-II in a Dutch study was high [19] , there is no study investigating this specifically in patients with LB. Screening for depressive symptoms in patients who are medically ill is difficult as somatic symptoms of depression may resemble symptoms of physical illness [26, 27] . In line with this, a study on depressive symptoms in patients with chronic hepatitis C concluded that questions targeting cognitive and affective symptoms may provide a more valid depression measurement than questions targeting somatic symptoms of depression [28] . This might also be the case for patients referred to a tertiary Lyme center, as the median of the somatic dimension of the BDI-II was higher than the medians of the affective and cognitive dimensions for both patients with clinical LB and positive serology and for patients with no clinical LB and negative serology. Studies concerning the BDI reported that 4.16% of the Spanish general population had a BDI score of ≥13 [29] , and 12% of US college students had a BDI-II score ≥20 [30] . Although in the Spanish study the BDI was used and not the BDI-II, the prevalence of moderate/severe depressive symptoms (ie, BDI-II score ≥20) in our study in all 4 patient groups was higher than the prevalence in the Spanish general population and US college students. Compared to healthy controls, it remains unknown whether LB is associated with moderate/severe depressive symptoms. We demonstrated that when comparing patients with and without LB referred to a tertiary Lyme center, LB is not associated with depressive symptoms. This is relevant for settings where physicians discriminate for LB in clinical practice.
A strength of our study is the large study population consisting of approximately 1500 patients. Another strength is the fact that patients were seen by both a neurologist and internist at the same time during the medical consultation. This reinforces the diagnosis based on clinical observation. Moreover, depressive symptoms were assessed with the Dutch version of the standardized BDI-II.
A limitation of our study is the fact that patients referred to a tertiary Lyme center may have long-term multiple subjective symptoms, which might predispose them to depression. This limits generalizability of study results. Another limitation is the retrospective design that allows for misinterpretation of the data extracted from the electronic patient record. This was minimized by the fact that in case of doubt concerning patient classification, a neurologist (B. v. K.) and an internist (Y. V.) reviewed the patient's medical record together to classify the patient. Moreover, besides age and sex, we did not control for other possible confounders of the association between depressive symptoms and LB, such as comorbidity, level of education, socioeconomic status, marital status, or other mental disorders (eg, anxiety or fatigue).
In patients with depressive symptoms and clinical LB with positive serology, no information was collected on whether or not patients were already depressed in the time preceding Lyme diagnosis. If this is the case, in these patients the depressive symptoms cannot be attributed to LB. These patients should theoretically not be included in the analyses for an association between LB and depressive symptoms. However, we were not able to correct for this possible bias.
In conclusion, this study showed that in patients referred to a tertiary Lyme center, depressive symptoms were common. To optimize care and treatment of patients suspected of LB visiting a tertiary Lyme center, we recommend patients to be screened for depressive symptoms so that, if indicated, they can benefit from psychological referral. Moreover, the prevalence of depressive symptoms was similar in patients with LB compared to patients with no evidence of infection. This suggests that depressive symptoms cannot be used to discriminate for LB in clinical practice in a tertiary Lyme center. 
